8F8.F SYNACT PHARMA AB
- Market cap
- EUR 75.7M
- P/E
- -
- P/B
- 5.92x
- ROE
- -74.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 8F8.F undervalued?
Graham numberThe Graham number of SYNACT PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SYNACT PHARMA AB fundamental analysis
No fundamental analysis for SYNACT PHARMA AB yet.
SYNACT PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SYNACT PHARMA AB
SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advance…
Full company profileSYNACT PHARMA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SYNACT PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -76.7M | -106M | -150M | -89.7M | -116M | -114M |
| EBITDA | - | -106M | -148M | -89.4M | -117M | -114M |
| Net Income | -69.3M | -99.2M | -216M | -82.4M | -111M | -106M |
| EPS | -2.63 | -3.32 | -6.01 | -1.77 | -2.08 | -1.90 |
| Balance Sheet | ||||||
| Total Assets | 38.4M | 143M | 228M | 271M | 221M | 229M |
| Total Liabilities | 17.5M | 16.1M | 51.8M | 56.4M | 50.2M | 87.1M |
| Shareholders' Equity | 20.9M | 127M | 176M | 214M | 170M | 142M |
| Cash & Short-term Investments | 24.0M | 108M | 62.4M | 61.2M | 53.4M | 42.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -65.0M | -118M | -100M | -89.2M | -97.3M | -115M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -65.0M | -118M | -100M | -89.2M | -97.3M | -115M |
| Ratios | ||||||
| ROE | -332.1% | -78.4% | -122.5% | -38.5% | -65.1% | -74.9% |
| ROA | -180.6% | -69.6% | -94.6% | -30.5% | -50.3% | -46.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
SYNACT PHARMA AB dividends
SYNACT PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns SYNACT PHARMA AB
- Insiders 25.30%
- Institutions 19.40%
- Public & others 55.30%
- Shares outstanding 56.0M
- Free float 37.8M
SYNACT PHARMA AB company profile
- Company name
- SYNACT PHARMA AB
- Ticker
- 8F8.F
- ISIN
- SE0008241491
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- ScheelevAegen 2, Lund, Sweden, 223 63
- Phone
- 46 1 03 00 10 23
- Website
- synactpharma.com
About SYNACT PHARMA AB
SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. The company has a strategic alliance with Hipolabor Farmacêutica LTDA for resomelagon in the treatment of dengue in Brazil. SynAct Pharma AB (publ) was founded in 2012 and is headquartered in Lund, Sweden.
SYNACT PHARMA AB management
6- Mr. Jeppe Ovli Ovlesen EE, MBAChief Executive Officer · born 1962
- Ms. Ann Kristin LedChief Financial Officer
- Dr. Thomas Boesen Ph.D.Chief Operating Officer
- Ms. Kristen Harting M.D.Chief Medical Officer
- Mr. Mads BjerregaardChief Business Officer
- Ms. Malin WikstrandFinancial Controller